Trial Profile
A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 30 Jun 2019 to 12 Apr 2019.